We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Partners to Offer Advanced Microscopy and Data Processing Solutions

By LabMedica International staff writers
Posted on 02 May 2011
Two German companies have signed a co-marketing agreement linking their advanced microscopy and software products.

Leica Microsystems GmbH (Wetzlar, Germany) is a leading global manufacturer of optical microscopes, equipment for the preparation of microscopic specimens, and related products. More...
The company manufactures products for applications requiring microscopic imaging, measurement, and analysis. It also offers system solutions in the areas of life science including biotechnology and medicine, as well as the science of raw materials and industrial quality assurance.

The partner company, Definiens (Munich, Germany), is a leading health image intelligence company that develops software solutions for biomedical image analysis, data mining, and clinical decision support. The company's software analyzes images from cell-based assays, whole tissue slides, and full body scans and allows users to correlate this information with data derived from other sources, supporting better decisions in research, diagnostics, and therapy.

Together the two companies will cooperatively market their complementary products and host joint workshops and educational events.

"Definiens and Leica Microsystems share a commitment to developing powerful imaging solutions that help researchers understand biological pathways faster and more accurately," said Thomas P. Heydler, CEO of Definiens. "This partnership will provide Leica customers with access to Definiens' advanced image analysis software, enabling high-content screening that directly aids drug discovery efforts around the world."

"Together with Definiens, we look forward to the opportunity to make highly developed and future-proof high content screening solutions widely available for academic research as well. The combination of high-sensitivity confocal technology, miniaturized sample handling, and reproducible evaluation with optimized data management is a sine qua non among drug discovery strategies and the analysis of their physiological relevance," said Dr. Stefan Traeger, managing director of the life science division of Leica Microsystems.

Related Links:
Leica Microsystems GmbH
Definiens





Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.